Clinical Trial Update: A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating LY2584702 combined with erlotinib or everolimus in patients with solid tumors was terminated, and results have been posted. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neuroendocrine Tumor
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Everolimus (everolimus)
• LY2584702 (LY2584702)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastases, Neoplasm, Carcinoma, Non-small Cell Lung | Phase 1 | Status: TERMINATED | Results posted: 2019-01-18